2014 Speakers and Videos
Dr. Sarah Darby
Professor of Medicine Statistics, Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford, England
Sarah C Darby is Professor of Medical Statistics in the University of Oxford. She studied for her PhD at the London School of Hygiene and Tropical Medicine. She then worked at St. Thomas’ Hospital Medical School, the National Radiological Protection Board, and the Radiation Effects Research Foundation in Hiroshima before moving to Oxford.
Keynote Presentation Topic: Risk of ischemic heart disease in women after radiotherapy for breast cancerRead More...
Sarah is a member of the secretariat of the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), which carries out meta-analyses of individual patient data from randomised controlled trials of various treatments for breast cancer, and she leads the EBCTCG analyses of the effects of radiotherapy and surgery. In addition, she leads a number of studies to evaluate the long-term risk of heart disease and other serious side-effects from cancer treatments and she works on several studies to evaluate the risk of cancer from exposure to ionising radiation.
Dr. Michael J. Fisch
Chair, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center Houston, TX
Dr. Fisch is Professor and Chair of the Department of General Oncology in the Division of Cancer Medicine at MD Anderson Cancer Center. He is the Principal Investigator of the MD Anderson Community Clinical Oncology Program (CCOP) Research Base, and this became the starting point for a newly developed Department of General Oncology led by Dr. Fisch since 2008.
Conference Topic: Introduction to the NCI National Community Oncology Research Program: What does NCORP mean to CardioOncology?Read More...
In addition, Dr. Fisch has served as Chair of the ECOG Symptom Management Committee (since 2006), and Co-Chair of the NCI Symptom Management and Quality of Life Committee (since 2007). He is a member of ICOS and has pursued cardio-oncology clinical research that bridges the academic and community oncology settings.
Dr. Thomas Force
Professor of Medicine, Clinical Director, Center for Translational Medicine, Temple University School of Medicine, Philadelphia, PA
Dr. Force is Professor of Medicine and Associate Director of the Center for Translational Medicine at Temple University School of Medicine. He received his A.B. from Harvard College, and his MD from Harvard Medical School. He completed his residency training in Internal Medicine at the University of Vermont, and his Cardiology fellowship at the West Roxbury VA Medical Center/Brigham & Women's Hospitals. Keynote Presentation Topic: Kinase inhibitors in cancer and the heart: Dealing with the other side of the coinRead More...
He was at the Massachusetts General Hospital from 1986 to 2000 where he served as the Medical Director of the Cardiovascular Health Center (1986-1993) and as the Director of the Stress Testing Laboratories (1993-1996), and in addition directed a basic research effort focused on identifying molecular mechanisms regulating growth and death of cardiac myocytes. He moved to the Molecular Cardiology Research Institute at Tufts University in 2000 to continue that work as Director of the Cardiomyocyte Biology Laboratory. He was Professor of Medicine at Tufts from 2000-2005 and then moved to Philadelphia. He is an Established Investigator of the American Heart Association, is the recipient of the Janice Pfeffer Award of the ISHR, and is President of the Heart Failure Society of America. He served on the editorial board of the Journal of Biological Chemistry (2000-2009) and is currently on the editorial boards of Circulation, Circulation Research, Circulation Heart Failure, and JACC. He recently chaired the Hypertrophic Cardiomyopathy Working Group of the NHLBI which focused on defining new clinical and basic research initiatives in the study of the disease. He is now co-chair of an NCI/NHLBI initiative addressing cardiotoxicity of cancer therapeutics. Finally, he is on the Basic Cardiovascular Sciences Council of the AHA. He will be moving to Vanderbilt University to direct the Cardiology Division's Basic and Clinical Science initiatives.
Dr. Daniel Lenihan
Professor of Medicine; Director, Clinical Research Program, Vanderbilt Heart and Vascular Institute, Nashville, TN
Dr. Lenihan, has been active in clinical research in cardiology, and specifically in heart failure, for nearly 20 years. The main focus of these efforts have included hemodynamic assessments, angiogenic growth factor response, novel cardiac biomarkers as well as optimal methods to prevent or detect heart failure at the earliest stage possible in patients undergoing treatment for cancer. His current projects include early phase clinical trials in heart failure, including the recently presented Phase 1 trial of GGF2 in cooperation with Acorda, Inc. Conference Topic: International CardiOncology Society: 2014 UpdateRead More...
As the Director of Clinical Research in the Division of Cardiovascular Medicine, Dr Lenihan is managing over 100 clinical trials in conjunction with all of VHVI faculty and continues to enhance and foster collaboration among a host of colleagues both internally and throughout the world. He is the current president (US/Canada) of the International CardiOncology Society, a professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.
Dr. Wael Maharsy
Postdoctoral Fellow, University of Ottawa Heart Institute, Ottawa, Ontario
Wael Maharsy, an international Postdoctoral Fellow from Lebanon, has a PhD degree in biochemistry from the University of Ottawa (2012). He gained his MSc. In physiology from the American University of Beirut (2006). Prior to his arrival to Ottawa, he worked at the Cardiac Development Research Unit at the Institut de Recherches Cliniques de Montreal (IRCM). Conference Topic: Ageing is a risk factor in imatinib mesylate cardiotoxicityRead More...
As a Postdoctoral Fellow and a PhD Student in the Molecular Genetics and Cardiac Regeneration Laboratory, he organized and performed a number of research projects on animal models and cell cultures. His work partly focused on deciphering the molecular pathways underlying the cardiac toxicity associated with various cancer drugs, and understanding the mechanisms implicated in survival of heart cells. Wael has also started working on a new project entitled the “Efficacy and Mechanism of Action of a Novel Class of Anticancer Drugs”. The objective of this project is to evaluate the potential anticancer properties of proprietary molecules. He will be testing the in vivo efficacy of these drugs on tumor regression in mice. This is critical for the development of these novel products into clinically effective drugs.
Dr. Javid Moslehi
Instructor, Department of Medicine, Harvard Medical School; Cardiologist, Brigham and Women’s Hospital, Boston, MA
Dr. Moslehi graduated from Johns Hopkins University and University of Connecticut School of Medicine. He completed an internship and residency in internal medicine at Johns Hopkins Hospital, followed by a cardiovascular fellowship at Brigham and Women's Hospital and Harvard Medical School. He then completed a post-doctoral fellowship at Dana-Farber Cancer Institute, focusing on the role of angiogenesis in heart disease.
Conference Topic: Cardio-Oncology: A New Platform for Basic and Translational InvestigationRead More...
Since 2009, Dr. Moslehi has established a "cardio-oncology" clinic at Daba-Farber Cancer Institute, providing care for cancer patients who develop cardiovascular complications during cancer treatment. Dr. Moslehi has an interest in the cardiovascular health of cancer survivors as well as potential cardiotoxicities of novel molecular targeted chemotherapies. His clinic is working to understand the mechanisms of toxicity associated with novel chemotherapies and is developing strategies to prevent and treat these complications.
Dr. Gillian Murtagh
MD, Fellow in Cardiac Imaging, The University of Chicago Medicine, Chicago, IL
Dr Murtagh is a Fellow in Cardio-Oncology and Advanced Cardiac Imaging at the University of Chicago Medical Center. She obtained her MD at Trinity College Dublin, and pursued her training in internal medicine in Ireland, New Zealand, Australia and the US, where she studied cardiac biomarkers with Dr Alan Maisel in San Diego, leading to her interest in the potential for biomarkers in predicting anti neoplastic therapy-related cardiac dysfunction. Conference Topic: Developing a Cardiac Oncology Fellowship ProgramRead More...
She returned to Ireland, launched a multicenter biomarker trial (ClinicalTrials.gov Identifier: NCT00968682), completed a fellowship in Cardiology and won a Young Cardiologist grant to further her interest in Cardio-Oncology. She was the first Cardiologist member of the All-Ireland Cooperative Oncology Research Network and recently instigated efforts to create a Cardio-Oncology Fellow-In-Training group internationally.
Dr. Edith Pituskin
Assistant Clinical Professor, Radiation Oncology, Cross Cancer Institute, Edmonton, AB
Dr. Edith Pituskin is an Assistant Clinical Professor in the Department of Oncology, University of Alberta. She is co-lead of the Edmonton Cardio-Oncology REsearch (ENCORE) program. Her PhD studies were specifically focused on cardiotoxicity of various cancer therapies. Dr Pituskin’s research interests include various preventive and treatment strategies of cardiotoxic cancer therapies, advanced practice and multidisciplinary team working, improving adherence to oral cancer therapies and program development.
Conference Topic: Opportunities and challenges in cardio-oncology clinical research
Dr. Rajeev Rao
Echocardiography Fellow, The University of Ottawa Heart Institute, Ottawa, ON
Dr. Rao comes from Richmond, B.C. and completed his undergraduate training at the University of British Columbia in Biochemistry and Molecular Biology. He completed his medical school at the University of Western Ontario followed by internal medicine training at the University of Toronto. Rajeev completed his cardiology fellowship at McMaster University and is currently in the second and final year of his echocardiography fellowship at the University of Ottawa Heart Institute. Dr. Rao’s clinical interests include echocardiography and its role in the management of cancer patients and valvular heart disease. Conference Topic: Echocardiography in the detection of cardio-toxicity
Dr. Jeffrey Sulpher
Cardiac Oncology Research Fellow, The Ottawa Hospital Cancer Centre, Ottawa, ON
Dr. Jeffrey Sulpher received his BSc.(Hons.) in Biopharmaceutical Sciences from the University of Ottawa in 2003, and his M.D. from Queen's University in 2008. He went on to complete his internal medicine and medical oncology residencies at the University of Ottawa. He is currently a cardiac oncology fellow at the Ottawa Hospital Cancer Centre.
Conference Topic: Cardiac Oncology Survey ResultsRead More...
His current research projects include the investigation of biomarkers for identification of patients at risk of treatment-induced cardiotoxicity, as well as a national physician's survey exploring issues surrounding cardiac oncology in Canada.
Dr. Paaladinesh Thavendiranathan
Cardiologist, Toronto General Hospital, Toronto, ON
Dr. Thavendiranathan in a Cardiologist and an Assistant Professor of Medicine at the Peter Munk Cardiac Center at the Toronto General Hospital (University of Toronto). He completed his Internal Medicine and Cardiology training at University of Toronto, followed by training in advanced cardiac imaging (echocardiography, cardiac CT, and cardiac MRI) at the Ohio State University Medical Center and the Cleveland Clinic.
Conference Topic: Role of cardiac MRI in the assessment of cardiotoxicityRead More...
His primary clinical interest is in the care of patients with cardiac toxicity from cancer therapy and currently runs the Cardiac Conditions in Oncology Program at University Health Network. As a Clinician Investigator his primary research interests are in use of novel imaging methods to identify early cardiac injury in patients receiving potentially cardio-toxic therapy and in studying various cardio-protective medications to prevent cardio-toxicity.